Education
About Us
Working with TipRanks
Follow Us
Lexston Life Sciences Corp. (TSE:LEXT)
:LEXT
LEXT Stock Chart & Stats
C$0.10
<C$0.01(11.11%)
At close: 4:00 PM EST
C$0.10
<C$0.01(11.11%)
Day’s Range― - ―
52-Week RangeC$0.06 - C$0.58
Previous CloseN/A
Volume1.00M
Average Volume (3M)40.70K
Market Cap
C$1.51M
Enterprise ValueC$424.29K
Total Cash (Recent Filing)C$17.46K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta-0.11
Next Earnings
Apr 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding25,093,304
10 Day Avg. Volume77,591
30 Day Avg. Volume40,703
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)13.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Reported DebtAbsence of debt lowers fixed obligations and interest burden, preserving liquidity runway and financial flexibility. For a company with minimal revenue, no debt reduces immediate solvency pressure and gives management time to pursue product development, restructure costs, or raise equity without servicing loans.
Improving Annual Net Losses (2022-2024)A multi-year reduction in reported annual losses demonstrates some progress in cost control or operational restructuring. If sustained, this trend reduces runway requirements, lowers future financing needs, and indicates management can tighten operations while preparing for eventual revenue generation.
Equity Rebound In TTMA rebound in equity suggests the company has been able to restore balance-sheet capacity, likely via capital raises or accounting adjustments. Restored equity improves solvency metrics, supports short-term liquidity, and provides a platform to fund strategic initiatives without immediate debt issuance.
Bears Say
Effectively Zero RevenueLack of recurring revenue is the most fundamental weakness: it prevents validation of market demand, blocks internal cash generation, and forces dependence on external funding. Over a multi-month horizon, absent a revenue ramp the company faces execution risk and limited ability to scale operations.
Persistent Negative Cash FlowSustained negative operating and free cash flow signals ongoing cash burn that will require additional financing if not reversed. This restricts the firm's ability to invest in commercialization or R&D, increases dilution risk from equity raises, and raises execution risk over the coming months.
Ongoing Unprofitability And Negative ROEPersistent net losses and negative ROE indicate the company is destroying shareholder value rather than creating it. Over time this undermines investor confidence, makes future capital raises harder or more dilutive, and signals structural challenges in converting resources into profitable operations.
Lexston Life Sciences Corp. News
LEXT FAQ
What was Lexston Life Sciences Corp.’s price range in the past 12 months?
Lexston Life Sciences Corp. lowest stock price was C$0.06 and its highest was C$0.58 in the past 12 months.
What is Lexston Life Sciences Corp.’s market cap?
Lexston Life Sciences Corp.’s market cap is C$1.51M.
When is Lexston Life Sciences Corp.’s upcoming earnings report date?
Lexston Life Sciences Corp.’s upcoming earnings report date is Apr 03, 2026 which is in 21 days.
How were Lexston Life Sciences Corp.’s earnings last quarter?
Lexston Life Sciences Corp. released its earnings results on Jan 14, 2026. The company reported -C$0.022 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.022.
Is Lexston Life Sciences Corp. overvalued?
According to Wall Street analysts Lexston Life Sciences Corp.’s price is currently Overvalued.
Does Lexston Life Sciences Corp. pay dividends?
Lexston Life Sciences Corp. does not currently pay dividends.
What is Lexston Life Sciences Corp.’s EPS estimate?
Lexston Life Sciences Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lexston Life Sciences Corp. have?
Lexston Life Sciences Corp. has 25,093,304 shares outstanding.
What happened to Lexston Life Sciences Corp.’s price movement after its last earnings report?
Lexston Life Sciences Corp. reported an EPS of -C$0.022 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.263%.
Which hedge fund is a major shareholder of Lexston Life Sciences Corp.?
Currently, no hedge funds are holding shares in TSE:LEXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lexston Life Sciences Corp.
Lexston Life Sciences Corp. operates as a biotechnology company that provides cannabis testing and research services in Canada. The company also offers analytical testing for cannabis, pathogens, and toxins. In addition, it focuses on developing and validating methods for standardized manufacturing of plant derived psychedelics in the field of mental health and wellness. The company is based in Vancouver, Canada.
Technical Analysis
Options Prices
Currently, No data available
---